FDA Accepts Ozekibart BLA with April 2027 PDUFA; CRC and INBRX-106 Data Add Momentum

What happened

Inhibrx Biosciences has passed a critical regulatory gate, with the FDA accepting its BLA for ozekibart in unresectable/metastatic chondrosarcoma and setting a PDUFA target action date of April 14, 2027. That acceptance converts the company's previously stated Q2 2026 filing intent into a concrete review timeline, removing the largest single downside scenario from the prior master report. Separately, positive interim data for ozekibart in 3rd/4th-line colorectal cancer and strong Phase 2 results for INBRX-106 plus KEYTRUDA in head and neck squamous cell carcinoma indicate broadening clinical utility beyond the lead indication. These data reduce the 'single-asset, single-indication' risk and support the pipeline optionality that earlier filings flagged as immature. Liver-safety management remains the key approval uncertainty, but the regulatory acceptance signals that the FDA sees a fileable package.

Implication

Investors should recognize that the FDA acceptance removes the binary timeline risk that underpinned the prior WAIT rating, and the April 2027 PDUFA date now anchors a defined approval catalyst. The positive CRC interim and INBRX-106 HNSCC Phase 2 data expand the addressable opportunity and suggest ozekibart's mechanism may have utility beyond a narrow rare-tumor niche. However, the stock has already re-rated significantly since the master report (price moved from $80.87 in February 2026 to an unspecified but likely higher level post-news), and approval is not guaranteed because liver-safety concerns from the program's history remain unresolved. Cash burn and pre-commercial spending continue, so financing risk exists even with a clearer regulatory path. A prudent approach is to hold/add on pullbacks rather than chase strength, monitoring any FDA advisory committee or label-safety signals leading up to the PDUFA date.

Thesis delta

The thesis shifts from WAIT to a more positive, catalyst-driven view. The prior concern centered on BLA filing timing and immature pipeline data; both have now been de-risked with FDA acceptance, a PDUFA date, and positive CRC/INBRX-106 data. The remaining risks are approval-specific (hepatotoxicity, label), commercialization execution, and funding, which are manageable but not eliminated.